Streetbeat News

EVOTF

Evotec SE

https://www.evotec.com/

CEO

Werner Lanthaler

Industry

Pharmaceutical Preparation Manufacturing

Open

6.96

Mkt cap

1.2B

Volume

100

High

6.96

P/E Ratio

-6.51

52-wk high

24.61

Low

6.77

Div yield

N/A

52-wk low

6.57

Evotec's insomnia drug, EVT201, has received approval from the Chinese medical authority through its partner Zhejiang Jingxin Pharmaceutical. Evotec is set to receive double-digit royalties on net sales and additional milestones based on commercial success and potential sub-licensing.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 7:04 am

Apple lost an appeal over 4G patent infringement in London court, marking another victory for Optis Cellular Technology. Deutsche Bank and Commerzbank face a $348M lawsuit by RusKhimAlyans, a Gazprom subsidiary. Nikola Corp plans to liquidate the assets of battery maker Romeo Power. Pfizer and Samsung Biologics signed two agreements for long-term manufacturing of Pfizer's biosimilar portfolio, worth $897M. Airbus is investing in a new Wing Technology Development Centre at its Filton site in the UK. TSMC expects a significant revenue rebound due to the launch of new Apple iPhones and strong demand for AI chips. Rivian Automotive reported Q2 production and delivery numbers. Evotec secured a US government contract for orthopoxvirus antibody. Mondelēz recalled two varieties of belVita biscuits in the US over peanut contamination. BYD plans to invest $620M in Brazil's Camaçari Industrial Complex. Alibaba is conducting a strategic review of video streaming platforms Youku and Tudou. UPS drivers consider going on strike after failed labor talks. OMV and ADNOC are in talks to create a chemicals and plastics company worth over $30B. Haleon is considering divesting some smoking cessation products to sell non-core businesses.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 1:23 pm

Evotec SE's subsidiary, Just - Evotec Biologics Inc, has been awarded a contract worth up to $74 million by the U.S. Department of Defense for the development of monoclonal antibody-based drug product prototypes targeting orthopoxviruses. The contract includes discovery activities and the execution of Phase 1 first-in-human trials. This follows a previous contract awarded in September 2022 for developing antibodies against plague. Additionally, Evotec has ongoing partnerships with Sanofi SA's Sandoz and Bristol Myers Squibb Co.

Portfolio Pulse from Vandana Singh

July 05, 2023 | 11:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.